Rochester, NY 6/15/2009 8:46:49 PM
Early Morning Gainers - Sourced WhisperFromWallStreet.com - JAZZ,BDSI,CTIC
Jazz Pharmaceuticals Inc - BioDelivery Sciences International, Inc. - Cell Therapeutics, Inc.
Early Morning Gainers - Sourced WhisperFromWallStreet.com - JAZZ,BDSI,CTIC
WhisperfromWallStreet.com is an award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, and teaching you how to become a better trader. We can now even deliver this information instantly to our "Penny Stock Alert" gadget that sits right on your Microsoft Vista or iGoogle desktop. You will know from the instant you get your confirmation email that we are different. What do you have to lose except a little time and a chance to really learn how to make money trading.
Sign up for our FREE alerts at WhisperfromWallStreet.com
---
Jazz Pharmaceuticals, Inc.,JAZZ
Jazz Pharmaceuticals Inc said its experimental treatment for fibromyalgia significantly reduced pain compared to the dummy drug in a late-stage trial, sending shares of the company up as much as 37 percent.
ABOUT
Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company's marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder. Its product candidate in Phase III clinical trials comprise JZP-6 for the treatment of fibromyalgia.
Last Trade: 2.64
Day's Range: N/A - N/A
52wk Range: 0.52 - 8.95
Volume: 512,771
---
BioDelivery Sciences International,BDSI
-BioDelivery Sciences International, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration’s (FDA) Division of Anesthesia, Analgesia and Rheumatology Products and a multidisciplinary review team on all aspects of the company’s New Drug Application (NDA) for ONSOLIS™ (fentanyl buccal soluble film), including the Risk Evaluation and Mitigation Strategy (REMS). Although the FDA did not meet its action date of last Friday for this NDA, the Division has informed the company that FDA will not be issuing a review extension letter as their action on the NDA is forthcoming.
ABOUT
BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB.
Last Trade: 6.76
Day's Range: N/A - N/A
52wk Range: 1.93 - 7.20
Volume: 260,739
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
---
Cell Therapeutics, Inc.,CTIC
Cell Therapeutics, Inc. announced that it has been included on a list of preliminary additions to the Russell 3000® Index and Russell Global® Index posted by Russell Investments on June 12, 2009 on www.russell.com. Russell Investments will reconstitute its family of U.S. and global equity indexes on June 26, 2009.
ABOUT
Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.
Last Trade: 1.43
Day's Range: N/A - N/A
52wk Range: 0.05 - 5.40
Volume: 2,945,006
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
